|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Ebola
|
|
gptkbp:activities
|
induces immune response
|
|
gptkbp:approves
|
gptkb:European_Medicines_Agency
gptkb:U._S._Food_and_Drug_Administration
|
|
gptkbp:average_temperature
|
-60 to -80 degrees Celsius
|
|
gptkbp:clinical_trial
|
gptkb:United_States
gptkb:Democratic_Republic_of_the_Congo
West Africa
Phase III trials
prevention of Ebola virus disease
|
|
gptkbp:defense
|
recommended for use in outbreaks
|
|
gptkbp:developed_by
|
gptkb:Merck_&_Co.
vesicular stomatitis virus
|
|
gptkbp:election_year
|
gptkb:2019
|
|
gptkbp:first_introduced
|
gptkb:2014
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
r VSV-ZEBOV
|
|
gptkbp:introduced
|
gptkb:2019
|
|
gptkbp:is_effective_against
|
approximately 97.5% in trials
ring vaccination strategy
|
|
gptkbp:is_vulnerable_to
|
gptkb:Coalition_for_Epidemic_Preparedness_Innovations
gptkb:Bill_&_Melinda_Gates_Foundation
gptkb:legislation
gptkb:Wellcome_Trust
gptkb:recombinant_vaccine
gptkb:U._S._National_Institutes_of_Health
cold chain logistics
single dose
cell-mediated immunity
viral vector platform
reduced Ebola transmission
strong humoral response
|
|
gptkbp:launch_date
|
gptkb:2001
gptkb:2014
|
|
gptkbp:license
|
gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:manager
|
subcutaneous injection
|
|
gptkbp:produced_by
|
cell culture
|
|
gptkbp:research_focus
|
Ebola outbreaks
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
fatigue
headache
mild fever
injection site pain
|
|
gptkbp:storage
|
requires ultra-cold chain
|
|
gptkbp:target_audience
|
high-risk individuals
|
|
gptkbp:targets
|
Ebola virus disease
|
|
gptkbp:type
|
live attenuated viral vaccine
|